期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三维适形放射治疗老年非小细胞肺癌60例 被引量：1

Analysis of curative effect on 60 elderly non-small cell lung cancer patients treated by three-dimensional conformal radiotherapy
在线阅读 下载PDF
导出
摘要 目的分析三维适形放疗(3DCRT)治疗老年非小细胞肺癌患者的临床疗效。方法60例老年非小细胞肺癌的患者,全部采用W DVE-XKY 808立体定向适形放射治疗系统。3DCRT处方剂量为DT 40~60 G y,中位剂量为50 G y,参考剂量曲线选定为80%~90%。分割方式:2~4 G y/次,每次间隔1~3天。结果肿瘤完全缓解率为30%(18/60),部分缓解率为45%(27/60),总有效率为75%(45/60)。1、2、3年生存率为66.3%、45.7%、30.3%。结论三维适形放疗(3DCRT)对老年非小细胞肺癌患者有较好的局部控制效果和较高的安全性,是治疗老年非小细胞肺癌患者的有效方法之一。 Objective To evaluate the curative effect on elderly non-small cell lung cancer patients treated by three-dimensional conformal radiotherapy(3DCRT).Methods 60 patients were treated by 3DCRT with a system of 6MV WDVE-XKY808.The total SRT dose was DT40 to 60 Gy prescribed at the 80%～90% isodose.2～4 Gy for the fraction size with an inter-fraction duration of 1～3 days.Results 30%(18/60) patients achieved complete remission,45%(27/60) achieved partial remission and total response rate was 75%(45/60).The overall ...
作者 周诚忠 夏炎春 夏海波
机构地区 解放军第
出处 《东南国防医药》 2009年第1期20-21,共2页 Military Medical Journal of Southeast China
关键词 非小细胞肺癌 放射疗法 三维适形放疗 Non-small cell lung cancer Radiotherapy Three-dimensional conformal radiotherapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献22

  • 1李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量：869
  • 2Brenner DJ, Hall EJ. Stereotactic radiotherapy of intracranial tumors: an ideal candidate for accelerated treatment. Int J Radiat Oncol Biol Phys, 1994, 28:1039-1041.
  • 3Larson DA, Flickinger JC, Loeffler JS. The radiobiology of radiosurgery. Int J Radiat Oncol Biol Phys, 1993,25:557-561.
  • 4Brenner DJ, Martel MK, Hall EJ. Fractionated regimes for stereotactic radiotherapy of recurrent tumor in the brain. Int J Radiat Oncol Biol Phys, 1991, 21:819-824.
  • 5Orton CG,Cohen L. A unified approach to dose-effect relationships in radiotherapy I: modified TDF and linear quadratic equations. Int J Radiat Oncol Biol Phys, 1988,14:549-556.
  • 6Fowler JF. Brief summary of radiobiological principles in fractionated radiotherapy. Sem Radiat Oncol, 1992, 2:16.
  • 7Ten Hakan RK, Frass BA, Lichter AS, et al. A brain tumor dose eacalation protocal based on effective dose equivalence to prior experience. Int J Radiat Oncol Biol Phys, 1998,42:137-141.
  • 8Rowell NP, Williams CJ. Radical Radiotherapy for stage Ⅰ / Ⅱ non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable ). The Cochrane Library,2001,2:1-11.
  • 9Perez CA, Stanley K, Rubin P,et al.A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of noperable non-oat cell carcinoma of the lung: preliminary report by RTOG. Cancer, 1980,45: 2744-2753.
  • 10Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable nonoat cell carcinoma of the lung treated with definitive radiotherapy: report by the RTOG. Cancer,1987,59:1874-1881.

共引文献114

同被引文献11

  • 1Dahabreh U, Linardou H, Siannis F, et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyro- sine kinase inhibitors in non-small cell lung cancer[ J ]. Clin Canc- er Res,2010,16( 1 ) :291-303.
  • 2Sholl LM, Xiao Y ,Joshi V, et al. EGFR mutation is a better predic- tor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry [ J ]. Am J Clin Patho1,2010,133 ( 6 ) :922-934.
  • 3Penzel R, Sers C, Chen Y, et al. EGFR mutation detection in NSCLC assessment of diagnostic application and recommenda- tions of the german panel for mutation testing in NSCLC [ J ]. Vir- chows Arch,2011,458( 1 ) :95-98.
  • 4Hart HS,Lim SN,An JY,et al. Detection of EGFR mutation status in lung adenocareinoma specimens with different proportions of tumor cells using two methods of differential sensitivity[ J]. J Tho- rac Onco1,2012,7 (2) :355-364.
  • 5Cheng H,Xu X,Costa DB,et al. Molecular testing in lung cancer: the time is now[ J]. Curr Oncol Rep,2010,12(5 ) :335-348.
  • 6Bardelli A, Janne PA. The road to resistance:EGFR mutation and cetuximab[ J]. Nat Med,2012,18(2) :199-200.
  • 7王晓萍,丰俊东.放射治疗与分子靶向药物在肿瘤治疗中的联合应用[J].东南国防医药,2008,10(4):277-280. 被引量：6
  • 8宋海珠,易俊,黄桂春,施毅.人肺腺癌细胞基因表型与尼妥珠单抗疗效的关系[J].医学研究生学报,2011,24(2):148-153. 被引量：8
  • 9王芳,付莎,汤涛,邓玲,张晓,李银珍,邵建永.非小细胞肺癌表皮生长因子受体基因突变与临床病理特征的关系[J].中华病理学杂志,2011,40(10):664-666. 被引量：24
  • 10王立帅,张瑜,陆小军,卢华君,周麟,王永生,邓磊,黄媚娟,彭枫,王瑾,任莉,侯梅,李潞,徐泳,应斌武,卢铀.双环探针特异引物荧光聚合酶链反应法检测非小细胞肺癌表皮生长因子受体基因突变[J].中华病理学杂志,2011,40(10):667-670. 被引量：12

引证文献1

二级引证文献4

东南国防医药
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部